Every 10-Q that Lisata Therapeutics Inc (LSTA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow LSTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LSTA filings page.
Lisata Therapeutics reported a net loss of about $4.5 million for the quarter ended March 31 2026, slightly improved from the prior year period. Operating expenses fell to $4.9 million as research and development dropped 53.7% to $1.2 million after winding down the BOLSTER trial and cutting clinical staff.
General and administrative costs rose 15.2% to $3.7 million, mainly from legal and consulting fees related to a proposed acquisition by Kuva Labs. Lisata ended the quarter with $13.1 million in cash and cash equivalents and working capital of about $10.7 million, but management concluded there is substantial doubt about the company’s ability to continue as a going concern without new funding.
Lisata terminated its Qilu license for certepetide in Greater China, eliminating up to $200 million in potential milestones and future royalties from that deal. Under a signed merger agreement, Kuva plans a tender offer at $5.00 per share plus a $1.00 contingent value right tied to future regulatory success for certepetide, though the offer has been delayed and may not be completed.
Lisata Therapeutics (LSTA) filed its Q3 2025 10‑Q, reporting a quarterly net loss of $4.249 million as operating expenses declined to $4.414 million from $5.336 million a year ago. Revenue was $0 in the quarter and $70 thousand year‑to‑date.
Liquidity and balance sheet: Cash and cash equivalents were $18.998 million, with total assets of $21.759 million and stockholders’ equity of $17.373 million as of September 30, 2025. The company states it has sufficient cash to meet funding requirements over the next 12 months and expects to seek additional financing by the end of 2026.
Operations and expenses: R&D was $1.959 million and G&A was $2.455 million in Q3. Year‑to‑date, R&D totaled $6.815 million and G&A $8.385 million. The company continued Phase 2 studies of certepetide and delayed certain Phase 3 readiness activities to manage cash.
Capital actions: Lisata raised $600,663 in net proceeds via its ATM during the nine months ended September 30, 2025 and sold $10.7 million of New Jersey NOLs for net proceeds of $871 thousand, recording a $962 thousand deferred income tax benefit.